- Childhood Cancer Survivors' Quality of Life
- Adolescent and Pediatric Healthcare
- Immune responses and vaccinations
- Vaccine Coverage and Hesitancy
- Ethics and Legal Issues in Pediatric Healthcare
- Health and Medical Research Impacts
- Biomedical Ethics and Regulation
- Health Systems, Economic Evaluations, Quality of Life
- Child and Adolescent Psychosocial and Emotional Development
- COVID-19 Impact on Reproduction
- Ethics in Clinical Research
- Bipolar Disorder and Treatment
- Cannabis and Cannabinoid Research
Orygen
2021
The University of Melbourne
2021
Background/Aims: Participants are integral to the success of any clinical research study, yet participant recruitment into trials poses ongoing and complex challenges. It is widely accepted recognised that trial sites often find it difficult meet goals, both in terms accrual targets timelines. This can impact validity or cause major delays for research. There very few frameworks available improve recruitment. The GREET project (Guidance Recruitment: Examining Experiences at Trial sites)...
Abstract Background No biological treatment has been firmly established for the at‐risk stage of psychotic disorder. In this study we aim to test if subthreshold symptoms can be effectively treated with cannabidiol (CBD), a non‐psychoactive compound plant Cannabis sativa . The question taken on increased importance in wake evidence questioning both need and efficacy specific pharmacological interventions ultra‐high risk (UHR) psychosis group. Methods Three‐arm randomized controlled trial 405...
Purpose: International data demonstrate association between clinical trial participation and reduced cancer mortality. Adolescents young adults (AYA) have low enrollment rates. We established a program to understand local barriers develop targeted solutions that lead greater AYA participation. Methods: A steering committee (SC) with expertise in adult pediatric oncology, research ethics, consumer representation was formed. The SC mapped related access working groups (WGs) around three...